ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 165 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2018. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $418,000 | -24.0% | 10,086 | +33.1% | 0.10% | -35.8% |
| Q1 2022 | $550,000 | +67.7% | 7,580 | +94.4% | 0.15% | +32.1% |
| Q4 2021 | $328,000 | +11.9% | 3,900 | +20.0% | 0.11% | +17.9% |
| Q3 2021 | $293,000 | +20.6% | 3,250 | +27.5% | 0.10% | -5.0% |
| Q2 2021 | $243,000 | -40.7% | 2,550 | -29.2% | 0.10% | -60.3% |
| Q1 2021 | $410,000 | -27.7% | 3,600 | -72.8% | 0.25% | +17.8% |
| Q3 2019 | $567,000 | +34.0% | 13,244 | +50.7% | 0.21% | -48.7% |
| Q4 2018 | $423,000 | – | 8,790 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |